Benefit and harms of new anti-cancer drugs (Q38084158)

28 August 2017

Benefit and harms of new anti-cancer drugs (English)

1 reference

28 August 2017

4

1 reference

28 August 2017

3

Arnoud J Templeton

1 reference

PubMed ID

23435854

28 August 2017

Francisco Vera-Badillo

series ordinal

1

object named as

Francisco E Vera-Badillo

1 reference

28 August 2017

Mustafa Al-Mubarak

2

1 reference

28 August 2017

1 June 2013

1 reference

28 August 2017

Current Oncology Reports

1 reference

28 August 2017

15

1 reference

28 August 2017

270-275

1 reference

28 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-013-0303-y

28 August 2017

0 references

cites work

What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions?

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0303-Y

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0303-Y

Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0303-Y

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0303-Y

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0303-Y

Surrogate end points in clinical trials: are we being misled?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0303-Y

Accelerated approval of oncology products: the food and drug administration experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0303-Y

Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0303-Y

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0303-Y

Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0303-Y

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0303-Y

Population-based differences in treatment outcome following anticancer drug therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0303-Y

Adverse events in randomized trials: neglected, restricted, distorted, and silenced.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0303-Y

Reporting of Safety Results in Published Reports of Randomized Controlled Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0303-Y

Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0303-Y

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0303-Y

Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0303-Y

Pathological complete response and accelerated drug approval in early breast cancer

21 January 2018

1 reference

12 December 2020

Adverse event detection in drug development: recommendations and obligations beyond phase 3

1 reference

12 December 2020

End points in cancer clinical trials and the drug approval process

1 reference

12 December 2020

Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval

1 reference

12 December 2020

Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials

1 reference

12 December 2020

New FDA regulation to improve safety reporting in clinical trials

1 reference

12 December 2020

The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs

1 reference

12 December 2020

Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer

1 reference

12 December 2020

Detecting an overall survival benefit that is derived from progression-free survival

1 reference

12 December 2020

Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs

1 reference

12 December 2020

Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point?

1 reference

12 December 2020

10.1007/S11912-013-0303-Y

Identifiers

DOI

1 reference

PubMed ID

23435854

Dimensions Publication ID

28 August 2017

0 references

1 reference

PubMed ID

23435854